Cytecare, committed to revolutionise Cancer care in India, announces the appointment of a Dr Mythri Shankar, Senior Consultant, Nuclear Medicine Department.
Dr Mythri Shankar has trained extensively in Nuclear Medicine from various globally renowned institutions such as UCLA, Cedars Sinai, Children’s Hospital of Los Angeles, and Harvard Medical School. With over 15 years of clinical expertise, Dr. Shankar’s experience has enabled the integration of most appropriate protocol selection while performing sophisticated radioactive injection procedures. She is a member of several international organizations such as the American Society of Nuclear Cardiology and the Society of Nuclear Medicine (USA & India), and is also actively involved in academics and several research projects.
Additionally, as a Physician, she has always placed paramount importance to education and continuous pursuit of excellence as the highest virtue. She has always followed her passion with an unerring and innate sense of direction beginning with her desire to practice evidence-based medicine both in the diagnostic and therapeutic arena of modern medicine (again as the first person to get a private license to use rubidium generator in the entire state of California) with a patient-friendly focus not just in philosophy but also in delivery of healthcare. She is a renowned Women’s Health Activist, an entrepreneur (IIM-B Alumini) and the Founder Trustee of‘Osteoporosis Foundation, India’.
Commenting on the appointment, Mr. Suresh Ramu, CEO & Co-Founder, Cytecare Hospitals, said “We are delighted to have Dr. Mythri Shankar on board as our Nuclear Medicine specialist. Targeted therapy with radiopharmaceuticals – radioactive compounds used in nuclear medicine for diagnosis or treatment has demonstrated superior clinical outcomes in trials for cancer treatment. Dr. Mythri’s joining the team will definitely be a great impetus for the Diagnostic & Nuclear medicine based therapy at Cytecare. With her specialized and research-based approach in nuclear medicine treatment. Cytecare is looking forward to her contribution in bringing innovation and strengthening the organ site approach for the hospital”.
